Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma
Cabozantinib plus atezolizumab was not a cost-effective treatment option for HCC when compared to sorafenib from both the Chinese healthcare system and the US payer perspectives.
Authors
- Tian Xia (ORCID: https://orcid.org/0009-0004-3376-9040)
- Rong Cai (ORCID: https://orcid.org/0000-0001-6793-5765)
- Zhaojun Bai (ORCID: https://orcid.org/0000-0002-1143-2429)
- Shousong Cao (ORCID: https://orcid.org/0000-0001-6892-0143)
- Cheng He (ORCID: https://orcid.org/0000-0003-4218-8454)
- Huijun Li (ORCID: https://orcid.org/0000-0003-2966-1569)
- Yan Zhu
Institutions
- Zunyi Medical University (CN)
- Guangxi Yuchai Machinery Group (China) (CN)
- First People’s Hospital of Zunyi (CN)
- WengFu Group (China) (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fphar.2025.1556304
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Guizhou Province
- Science and Technology Program of Guizhou Province